All In Biotech

NDA 022150 · Takeda Pharms USA

Firazyr

Icatibant Acetate · Subcutaneous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Aug 25, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

26

11 Phase 3, 0 recruiting

FAERS reports

6,011

4,052 serious, 155 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2025.

FIRAZYR ® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. FIRAZYR is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )

Mechanism: Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 25, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelLetter
1 products under this application
  • FIRAZYR · ICATIBANT ACETATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Icatibant" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema2,634
  • drug ineffective504
  • product dose omission issue451
  • weight decreased415
  • weight increased379
  • injection site pain307
  • off label use277
  • product use issue275
  • inappropriate schedule of product administration243
  • headache234
  • stress217
  • condition aggravated203

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20114
201246
2013219
2014215
2015384
2016400
2017296
2018622
2019586
2020406
2021422
2022456
2023504
2024442
2025503
2026505

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Firazyr (Icatibant Acetate)

2024 spending

$43.7M

Beneficiaries

170

719 claims

Per beneficiary

$257,140

$3,553.97 per unit

View as table
YearSpending
2020$72,629,982
2021$61,220,572
2022$61,586,152
2023$56,351,521
2024$43,713,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.